Last reviewed · How we verify
NCT01672905
PSA Antibody Levels in Samples From Patients With Prostate Cancer Treated on Protocol ECOG-E9802
trial testing laboratory biomarker analysis in Prostate Cancer in 20 participants. Completed in 7 January 2013.
7 January 2013
Quick facts
| Lead sponsor | Eastern Cooperative Oncology Group |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 20 |
| Start date | 7 December 2012 |
| Primary completion | 7 January 2013 |
| Estimated completion | 7 January 2013 |
Drugs / interventions tested
- laboratory biomarker analysis — full drug profile →
Conditions studied
- Prostate Cancer — all drugs for Prostate Cancer →
Sponsor
Eastern Cooperative Oncology Group
Who can join
Adults 18 to 120, male only, with Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
RATIONALE: Studying samples of blood or tumor tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer. PURPOSE: This clinical trial studies prostate-specific antigen (PSA) antibody levels in samples from patients treated for prostate cancer on trial ECOG-E9802.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT01672905
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of laboratory biomarker analysis
Trials testing the same drug.
- NCT07492823 — Clinical Applicability of Liquid Biopsy in Chondrosarcoma · not yet recruiting
- NCT07411612 — The Association Between Postoperative Inflammatory and Neurological Serum Biomarker Concentrations and Occurrence of Pos · recruiting
- NCT07375433 — Heart Failure With Preserved Ejection Fraction in Patients With Сhronic Obstructive Pulmonary Disease: Clinical Course a · recruiting
- NCT05388773 — Transoral Surgical Resection Followed by De-escalated Adjuvant IMRT in Resectable p16+ Locally Advanced Oropharynx Cance · Phase 2 · recruiting
- NCT02122172 — Afatinib in Advanced Refractory Urothelial Cancer · Phase 2 · terminated
Other recruiting trials for Prostate Cancer
Currently open trials in the same condition.
- NCT06960798 — Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno) · recruiting
- NCT07237269 — Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer · Phase 2 · recruiting
- NCT07234981 — PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer · Phase 2 · recruiting
- NCT07027124 — Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Ris · Phase 2 · recruiting
- NCT07426094 — PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate · Phase 2, PHASE3 · recruiting
Other Eastern Cooperative Oncology Group trials
Trials by the same sponsor.
- NCT07068074 — A Randomized Phase III Study of Management of Treatment Naive Primary Melanoma in Elderly Patients · Phase 3 · not yet recruiting
- NCT07040280 — Testing the Effect of Sulforaphane, a Compound Naturally Found in Cruciferous Vegetables, on Preventing Melanoma in Pati · Phase 2 · not yet recruiting
- NCT07122492 — A Targeted Electronic Health Approach to Reduce Fear of Recurrence in Breast Cancer Survivors (FoRtitude) · NA · not yet recruiting
- NCT07085728 — Testing the Investigational Agent Combination of Daratumumab, Bortezomib, and Dexamethasone Compared to the Usual Treatm · Phase 2 · not yet recruiting
- NCT06756607 — The ECOG-ACRIN SUPPORT Trial: Multilevel Intervention to Improve Diverse Enrollment in Cancer Clinical Trials · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT01672905 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Eastern Cooperative Oncology Group
- Last refreshed: 17 May 2017
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01672905.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing